Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2003, p. 2971-2973, Vol. 47, No. 9
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.9.2971-2973.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Bacteriology, Swedish Institute for Infectious Disease Control,1 Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden,2 Department of Mycobacteriology, United Laboratory, Tartu University Clinics, Tartu,3 North-Estonian Regional Hospital, Tallinn, Estonia4
Received 28 January 2003/ Returned for modification 3 April 2003/ Accepted 19 June 2003
It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»